Physician profile
David Lee
NPI 1225359847
$2,304.32
in general payments reported to CMS, 2019-2025
15 companies · $295 in 2025
The $295 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.14 · 2020: $11.57 · 2021: $90.56 · 2022: $1,512 · 2023: $268 · 2024: $80.86 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,500.00 | 2022 | |
| Alcon Vision LLC | $324.41 | 2019-2025 | Clareon, Simbrinza, Rocklatan |
| Apellis Pharmaceuticals, INC. | $138.54 | 2023-2024 | Syfovre |
| Abbvie INC. | $66.93 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $63.75 | 2020-2025 | |
| Akorn Operating Company LLC | $52.01 | 2021 | |
| Glaukos Corporation | $26.16 | 2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.14 | 2019 | |
| Ani Pharmaceuticals, INC. | $18.92 | 2025 | Purified Cortrophin Gel |
| Sight Sciences, INC. | $17.62 | 2023 | Omni Surgical System |
| Bausch & Lomb Americas INC. | $16.48 | 2023 | Lotemax Sm, Prolensa, Vyzulta |
| Amgen INC. | $15.07 | 2025 | Tepezza |
| Harrow Eye, LLC | $14.75 | 2024 | Iheezo |
| Tarsus Pharmaceuticals, INC. | $14.15 | 2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $13.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.